THURSDAY, Dec. 29, 2022 (HealthDay News) — The U.S. Food and Drug Administration’s approval process for the controversial Alzheimer’s drug Aduhelm was “rife with irregularities,” despite lingering doubts about the power of the pricey medication to slow the disease down, a Congressional report released Thursday claims. Actions the agency tookContinue Reading

THURSDAY, Dec. 22, 2022 (HealthDay News) — Researchers are studying whether deep brain stimulation could help people with Alzheimer’s hold on to their memory longer, and now a new finding may help refine the approach. Deep brain stimulation (DBS) is an established treatment for several medical conditions, including epilepsy, Parkinson’sContinue Reading

WEDNESDAY, Dec. 21, 2022 (HealthDay News) — Groups of whales, dolphins and porpoises are regularly stranded in shallow waters around the coasts of the United Kingdom. Researchers wanted to understand why, so they studied the brains of 22 toothed whales — or “odontocetes” — that were stranded in Scottish coastalContinue Reading

WEDNESDAY, Nov. 30, 2022 (HealthDay News) — The experimental Alzheimer’s drug lecanemab slowed thinking declines among patients suffering the early stages of the disease in a new study, but safety concerns about brain swelling and brain bleeds remain. In the eagerly awaited trial findings, published Tuesday in the New EnglandContinue Reading

TUESDAY, Nov. 29, 2022 (HealthDay News) — Two people have now died from brain hemorrhages that may be linked to an experimental Alzheimer’s drug, calling into question the medication’s safety. A 65-year-old woman with early-stage Alzheimer’s recently died from a massive brain bleed that some researchers link to lecanemab, anContinue Reading